The purpose of this study is to assess the effects of steady state DCV/ASV/BMS-791325 fixed
dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of Methadone in
subjects with the stable dose of Methadone and on the PK of Buprenorphine in subjects with
the stable dose of Buprenorphine.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Buprenorphine Buprenorphine, Naloxone Drug Combination Methadone Naloxone